Status:
UNKNOWN
Copaxone in Age Related Macular Degeneration
Lead Sponsor:
Kaplan Medical Center
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effe...
Detailed Description
The formation of insoluble extracellular deposits consisting of misfolded, aggregated protein is the hallmark of many neurodegenerative diseases. Age-related macular degeneration (AMD) is a degenerati...
Eligibility Criteria
Inclusion
- Dry AMD in both eyes
- Age 50 or above.
- Signed informed consent.
Exclusion
- Known sensitivity to mannitol or Copaxone.
- Skin disease or active infection of skin.
- Active fever or active treatment for infection.
- History of other active disaese.
- Premenapausal females not using relibale birth control.
- Sensitivity for flourescein or iodine.
- Inability to comply with study procedures.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00466076
Start Date
August 1 2006
End Date
April 1 2007
Last Update
April 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Kaplan Medical Center
Rehovot, Israel, 76100